Related Experiment Video
Updated: Jul 5, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Acute liver failure due to drugs
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109-0362, USA. rfontana@med.umich.edu
Seminars in Liver Disease
|May 3, 2008
Summary
Acetaminophen overdose and idiosyncratic drug-induced liver injury (DILI) cause most US acute liver failure (ALF). While acetaminophen hepatotoxicity is treatable, DILI lacks effective treatments, necessitating further research into biomarkers.
Area of Science:
- Hepatology
- Toxicology
- Immunology
Background:
- Acetaminophen overdose and idiosyncratic drug-induced liver injury (DILI) are leading causes of acute liver failure (ALF) in the United States.
- Acetaminophen hepatotoxicity is preventable and treatable with N-acetylcysteine, yet approximately 500 deaths occur annually.
- Idiosyncratic DILI is currently not preventable due to limited understanding of host susceptibility and outcome predictors.
Purpose of the Study:
- To review the current understanding of acetaminophen overdose and idiosyncratic DILI as causes of ALF.
- To highlight the challenges in diagnosing and treating idiosyncratic DILI.
- To emphasize the need for research into host variability for improved diagnostics and prognostics.
Main Methods:
- Literature review and synthesis of existing data on acetaminophen hepatotoxicity and DILI.
- Analysis of proposed strategies for reducing acetaminophen-related liver injury.
- Discussion of current diagnostic and treatment limitations for idiosyncratic DILI.
Main Results:
- Acetaminophen overdose remains a significant cause of preventable ALF despite available treatments.
- Idiosyncratic DILI presents diagnostic challenges and has a poor prognosis without established medical interventions.
- Urgent referral to transplant centers is recommended for severe idiosyncratic DILI cases.
Conclusions:
- Further investigation into host variability in metabolic, regenerative, and immune pathways is crucial.
- Identifying molecular underpinnings of DILI can lead to improved diagnostic and prognostic biomarkers.
- Research is needed to develop effective treatments for idiosyncratic DILI.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...